Amorphous Solid Dispersion: Strategies in Early Stage Development and Technology Choice

3/17/2021 14:05 - 14:40

  • Many ASD technologies are available at the industrial scale
  • Selection of the right technology is strategic for the future development pre-clinical and clinical such as
    • Quantity of API available for early development studies
    • Stage of development (feasibility studies, formulation/process development)
    • Formulation selection
    • CMC prerequisite (physical and chemical stability, solubility and dissolution improvement)
    • Biological performance enhancements.
This talk will describe how to make early pre-formulation appropriated strategic choices for these complex ASD formulations with tangible case studies.

Philippe Lienard, Pre-Development Science Leader, Sanofi